Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults노인에서 COVID-19 mRNA 백신에 대한 체액성 면역 반응의 크기 및 내구성 감소Major Article Published on 2021-12-092022-09-10 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE2 activity Adults age All participants antibodies antibody binding antibodies binding antibody characterized correction COVID-19 COVID-19 mRNA vaccine COVID-19 mRNA vaccines declined delta variant elevated evaluated except for exhibited health condition healthcare worker humoral humoral immune response Humoral response humoral responses immune response immune responses magnitude measure mRNA vaccine mRNA vaccines Neutralizing activity Older older adult Older adults Older age Participants plasma RBD reduced remained response Result risk of infection second dose significantly significantly lower sociodemographic factors tested vaccination vaccine dose variables viral neutralization virus were assessed [DOI] 10.1093/infdis/jiab592 PMC 바로가기 [Article Type] Major Article
Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta VariantArticle Published on 2021-12-072022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] 95% CI 95% confidence interval Affect antibody response against BNT162b2 BNT162b2 vaccine boost booster booster dose CoronaVac COVID-19 Delta delta variant Delta variants dose geometric mean titre GMT group groups immune response increase increase in Increases individual Live virus mRNA vaccine naïve subject Neutralization assay Neutralizing activity neutralizing antibody no difference of BNT162b2 Patient receiving recovered recovered patient recruited reduced response SARS-CoV-2 sera significantly subjects the SARS-CoV-2 Type Vaccinating vaccination Vaccine vaccine platform Vaccines virus was determined wild-type [DOI] 10.3390/vaccines9121442 PMC 바로가기 [Article Type] Article
Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants백신 접종과 결합된 이전 감염은 SARS-CoV-2 변이체에 대한 효능이 있는 중화 항체를 생성합니다Observation Published on 2021-12-072022-09-10 Journal: mBio [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus antibody antigenic antiviral activity biologic Combined coronavirus COVID-19 Efficacy evade humans Humoral immunity IMPROVE Infection Mutation Neutralizing Neutralizing activity potency Produce Protein raised reduce respiratory SARS-CoV-2 SARS-COV-2 infection sequence serum severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 spike spike mutation Spike protein spike variants tested Transmission vaccination vaccine efficacy Vaccines variants [DOI] 10.1128/mBio.02656-21 PMC 바로가기 [Article Type] Observation
A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters생약독화 파라인플루엔자 바이러스 매개 SARS-CoV-2 백신의 단일 비강 투여는 햄스터를 보호합니다423 Published on 2021-12-072022-09-12 Journal: Proceedings of the National Academy of Sciences of [Category] Coronavirus, SARS, 진단, [키워드] age all age groups antibody Antigen B.1.1.7 B.1.351 children chimeric clinical evaluation contribute COVID-19 dose effort evaluated exhibited Express expressed expressing expression fold generally mild hamster hamsters IgA IgG immunization immunogenic Infant Infants intranasal intranasal immunization intranasally Lineage lineages lung Lungs manuscript moderate morbidity nasal tissue neutralization Neutralizing activity parainfluenza parainfluenza virus parainfluenza virus 3 parainfluenza virus vaccines pediatric prefusion PROTECT Protective Receptor binding domain replicated Replication respiratory tract restrict robust S protein S-2P SARS-CoV-2 SARS-CoV-2 infections SARS-CoV-2 replication SARS-CoV-2 S SARS-CoV-2 S protein SARS-CoV-2 vaccine SARS-CoV-2 vaccines serum Significance significantly higher Single-dose Spike protein TCID the SARS-CoV-2 titers Transmission dynamics undetectable Vaccine vaccine candidate vaccine vector vector vectors virus was reduced weight loss [DOI] 10.1073/pnas.2109744118 PMC 바로가기 [Article Type] 423
Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization불 활성화 된 SARS-COV-2 바이러스 면역 후 감마 및 제타 변이체에 대한 보호 면역Article Published on 2021-12-042022-09-01 Journal: Viruses [Category] SARS, 변종, 진단, [키워드] addition anti-S antibody antibody production cellular response circulation conducted COVID-19 cross-protection cross-reactive demonstrated evade evaluated follow-up study Gamma Gamma variant histopathological IgG IL-6 IL-6 expression immune response immune system Immunity immunization immunized immunized mice inactivated Inactivated vaccine increase individual induce Infection levels of antibody Lungs mice mice immunization Neutralizing activity outcome pathological outcome pathological outcomes performed produced Production reduced reduced viral loads reducing robust SARS-CoV-2 SARS-CoV-2 vaccine Serum Neutralization significantly TNF vaccinated individuals vaccination variant variants Viral viral infection viral loads viral variant WT SARS-CoV-2 Zeta variant [DOI] 10.3390/v13122440 PMC 바로가기 [Article Type] Article
Long-term trajectories of SARS-CoV-2 neutralizing antibodies and predictive value of first dose vaccination-induced IgG-antibodies in hemodialysis patients혈액투석 환자에서 SARS-CoV-2 중화항체의 장기 궤적과 1차 접종으로 유도된 IgG 항체의 예측가Nephrology - Original Paper Published on 2021-12-032022-09-12 Journal: International urology and nephrology [Category] SARS, 진단, [키워드] 95% CI Accuracy analysed Analysis ANOVA Antibody titer Antibody titer trajectory Antibody titers baseline calculate Chi-squared test comparable COVID-19 declined dialysis Effectiveness Evidence evidence of Evolution Factor first and second dose first dose first vaccination Follow-up General population healthy controls Hemodialysis IgG IgG antibodies IgG antibody IgG titer IgG titers immunization immunosuppressive Immunosuppressive medication immunosuppressive therapy Long-term follow-up low-dose medication Neutralizing Neutralizing activity Neutralizing antibodies neutralizing capacity neutralizing effect non-responder outcome over participant Patient patients per day positive IgG antibodies Post-vaccine potential risk predict predicted Predictive Predictive value Protective Relative risk remained Responder responders Result risk risk factor SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody SARS-CoV-2 neutralizing antibody SARS-CoV-2 vaccination second dose second vaccination sensitivity seroconversion rate specificity therapy trajectory vaccination was performed [DOI] 10.1007/s11255-021-03076-2 PMC 바로가기 [Article Type] Nephrology - Original Paper
Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced ImmunityBNT162b2 SARS-CoV-2 백신 유도 면역의 알파 및 베타 변이체에 대한 중화의 연령 의존적 감소Research Article Published on 2021-12-012022-09-10 Journal: Microbiology Spectrum [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 age All participants anti-RBD antibody antibody level antibody levels Antibody test Antigen basic Beta binding domain BNT162b2 BNT162b2 vaccine Clinical characteristics collected Coronavirus-2 correlated Cutoff decrease female groups Health care Health care worker health care workers heterogeneity high risk higher risk Humoral immunity Immunity include individual Infection interquartile range introduced IQR median mRNA vaccine mRNA vaccines neutralization Neutralizing Neutralizing activity Neutralizing antibodies of BNT162b2 Older age participant Patient patient age positive Pseudotyped virus questionnaire Questionnaires Randomly Receptor-binding domain reduction respiratory SARS-CoV-2 SARS-COV-2 infection second dose selected sera serum dilution Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Spike protein Toyama U/mL university vaccination variant variants Viral viral variant Viral variants virus viruses was obtained were measured wild type wild-type wild-type SARS-CoV-2 wild-type virus [DOI] 10.1128/Spectrum.00561-21 PMC 바로가기 [Article Type] Research Article
Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants상업용 Anti-SARS-CoV-2 수용체 결합 도메인 항체 테스트와 화학발광 환원 중화 테스트의 상관관계 및 항체의 새로운 변이체 검출 가능Research Article Published on 2021-12-012022-09-10 Journal: Microbiology Spectrum [Category] SARS, 변종, 진단, 치료기술, [키워드] 95% confidence interval Accuracy acquisition acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 anti-RBD anti-receptor-binding domain Antibody test antibody test result antibody tests B.1.1.7 B.1.351 B.1.351 variant B.1.351 variants biohazard clinical laboratory close contact comparable convalescent convalescent COVID-19 patients convalescent phase Coronavirus-2 correlated correlation COVID-19 COVID-19 patient COVID-19 patients Critical defined detection diagnostic disease onset displaying Efficacy episode episode of Evidence evidence of functional healthy individual high throughput identify immune response Immunity indicate Laboratory lead neutralization Neutralizing Neutralizing activity Neutralizing antibodies Neutralizing titer neutralizing titers optimization Patient PCR-negative positive result proof protective immunity provide Pseudotyped virus Pseudotyped viruses Quantitative RBD Receptor-binding domain recognizing reduction respiratory SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Seroconversion serological test Serological tests serology serum sample serum samples Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Spike protein Strong symptomatic Test test validity Vaccine vaccine efficacy Validity variant variants virus viruses wild-type [DOI] 10.1128/Spectrum.00560-21 PMC 바로가기 [Article Type] Research Article
Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients고형 장기 이식 환자에서 동종 및 이종 mRNA 및 벡터 기반 COVID-19 백신 요법 후 체액성 면역보다 세포 면역이 우세합니다.Article Published on 2021-12-012022-09-11 Journal: American journal of transplantation : official jou [Category] SARS, 진단, 치료기술, [키워드] Analysis analyzed antibody CD4 CD4 and CD8 T cells CD4 T cells CD8 T cell CD8 T cells Cell Biology cellular immunity clinical research/practice Control correlated COVID-19 vaccine ELISA first vaccination flow cytometry Heterologous heterologous vaccine homologous homologous or heterologous humoral humoral and cellular immunity Humoral immunity identify IgG Immunity immunocompromised individuals immunogenicity IMPROVE Infection infection and infectious agents - viral infectious agent infectious agents Infectious disease mRNA mRNA-vaccine mRNA-vaccines Neutralization assay Neutralizing activity patients plasmablast plasmablasts priming quantified recipient recipients regimen regimens Responder responders SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody SARS-CoV-2-specific IgG SARS-CoV-2-specific T cell SARS-CoV-2-specific T cells second vaccination significantly higher solid organ solid organ transplant Specific specific antibodies T cell T cell biology T cells vaccination Vaccine while [DOI] 10.1111/ajt.16818 PMC 바로가기 [Article Type] Article
Nanoparticular CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in miceResearch article Published on 2021-12-012022-10-05 Journal: International journal of biological macromolecules [Category] SARS, 비임상, [키워드] Antigen antigenicity approach cellular response characterized COVID-19 COVID-19 vaccine CpG adjuvant Critical cross-protective domain elicit enzyme-linked immunosorbent Fucoidan-trimethylchitosan nanoparticles IgG IgG response Immunogenicity enhancement Immunoglobulin immunoreactivity IMPROVE induce investigated long-lasting mice monoclonal antibody Neutralization assay Neutralizing Neutralizing activity neutralizing antibody Protective Protein pseudovirus RBD Recombinant S1 protein S protein S1 domain SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 S1 protein SARS-CoV-2 variant Th1-biased cellular immune responses the RBD vaccination vaccine candidate were assessed [DOI] 10.1016/j.ijbiomac.2021.11.020 [Article Type] Research article